The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
Open accessAbstract
We report a new nanoparticle system for chemoimmunotherapy that elicits robust antitumor immunity against established tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 4×
“Notably, recent studies have shown that certain chemotherapeutic drugs, such as doxorubicin (DOX), may contribute to antitumor T cell responses by inducing a special form of tumor-cell killing, known as immunogenic cell death (ICD) ( 17 – 22 ).”
BackgroundInfluentialRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Recent studies have shown that the antitumor efficacy of immune checkpoint blockade is strongly correlated with T cell responses against neoantigens, which are antigens encoded by somatic gene mutations only found in cancerous cells ( 41 , 43 , 50 ).”
BackgroundGhiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Antiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Self-citationCancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Andrew MacKay, J., Chen, M., McDaniel, J. R., Liu, W., Simnick, A. J., & Chilkoti, A. (2009) · Nature Materials · doi:10.1038/nmat2569 · Cited by 580
Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 557
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
Arola, O., Saraste, A., Pulkki, K. J., Kallajoki, M. A., Parvinen, M., & Voipio-Pulkki, L. M. (2000) · PubMed · Cited by 494
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
High-Density Lipoproteins: Nature’s Multifunctional Nanoparticles
Kuai, R., Li, D., Chen, Y. E., Moon, J. J., & Schwendeman, A. (2016) · ACS Nano · doi:10.1021/acsnano.5b07522 · Cited by 338
Self-citationAnti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Mathios, D., Kim, J. E., Mangraviti, A., Phallen, J., Park, C.-K., Jackson, C. M., Garzon-Muvdi, T., Kim, E., Theodros, D., Polanczyk, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2942 · Cited by 296
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)
Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl477 · Cited by 265
Cooney, M. T., Dudina, A., De Bacquer, D., Wilhelmsen, L., Sans, S., Menotti, A., De Backer, G., Jousilahti, P., Keil, U., Thomsen, T., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.041 · Cited by 250
Belcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S., Kellett, M., Ruzevick, J., Jackson, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 244
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting
Rensen, P. C. N., de Vrueh, R. L. A., Kuiper, J., Bijsterbosch, M. K., Biessen, E. A. L., & van Berkel, T. J. C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00109-0 · Cited by 215
Maksimenko, A., Dosio, F., Mougin, J., Ferrero, A., Wack, S., Reddy, L. H., Weyn, A.-A., Lepeltier, E., Bourgaux, C., Stella, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313459110 · Cited by 212
Rios-Doria, J., Durham, N., Wetzel, L., Rothstein, R., Chesebrough, J., Holoweckyj, N., Zhao, W., Leow, C. C., & Hollingsworth, R. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.004 · Cited by 174
A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics
Cui, L., Lin, Q., Jin, C. S., Jiang, W., Huang, H., Ding, L., Muhanna, N., Irish, J. C., Wang, F., Chen, J., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b01077 · Cited by 172
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Catani, J. P. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 149
Etrych, T., Šubr, V., Strohalm, J., Šírová, M., Říhová, B., & Ulbrich, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.029 · Cited by 142
Ye, D.-X., Ma, Y., Zhao, W., Cao, H., Kong, J., Xiong, H., & Möhwald, H. (2016) · ACS Nano · doi:10.1021/acsnano.5b07846 · Cited by 115
Schwendeman, A. A., Sviridov, D. O., Yuan, W., Guo, Y., Morin, E. E., Yuan, Y., Stonik, J. A., Freeman, L. A., Ossoli, A., Thacker, S. G., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060285 · Cited by 106
Self-citationKang, T. H., Mao, C.-P., Lee, S. Y., Chen, A. J., Lee, J., Kim, T. W., Alvarez, R. D., Roden, R. B. S., Pardoll, D. M., Hung, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4241 · Cited by 104
Ogawara, K.-I., Un, K., Tanaka, K.-I., Higaki, K., & Kimura, T. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.008 · Cited by 101
van der Sluis, T. C., van Duikeren, S., Huppelschoten, S., Jordanova, E. S., Nejad, E. B., Sloots, A., Boon, L., Smit, V. T. H. B. M., Welters, M. J. P., OSSENDORP, F. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2142 · Cited by 92
Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis
Frias, M. A., Lang, U., Gerber-Wicht, C., & James, R. W. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp289 · Cited by 88
Local and transient gene expression primes the liver to resist cancer metastasis
Goodwin, T. J., Zhou, Y., Musetti, S., Liu, R., & Huang, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2306 · Cited by 80
Cho, H. I., Barrios, K., Lee, Y.-R., Linowski, A. K., & Celis, E. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1382-6 · Cited by 76
Zhang, Y., Davis, C., Ryan, J. C., Janney, C., & Peña, M. M. O. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9591-8 · Cited by 68
Tang, J., Kuai, R., Yuan, W., Drake, L. R., Moon, J. J., & Schwendeman, A. A. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.04.009 · Cited by 61
Self-citationSynthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin
Yuan, Y., Wen, J., Tang, J., Kan, Q., Ackermann, R., Olsen, K. F., & Schwendeman, A. A. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s112835 · Cited by 44
Self-citationApolipoprotein Mimetic Peptides for Stimulating Cholesterol Efflux
Li, D., Gordon, S. M., Schwendeman, A. A., & Remaley, A. T. (2015) · Springer eBooks · doi:10.1007/978-3-319-17350-4_3 · Cited by 31
Self-citationSubramanian, C., Kuai, R., Zhu, Q., White, P., Moon, J. J., Schwendeman, A. A., & Cohen, M. S. (2015) · Surgery · doi:10.1016/j.surg.2015.08.023 · Cited by 31
Self-citation
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Self-citationEnhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Sun, X., Zhang, Y., Li, J., Park, K. S., Han, K., Zhou, X., Xu, Y., Nam, J., Xu, J., Shi, X., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00962-9 · Cited by 788
Self-citation
Metadata
- Authors
- Kuai, R., Yuan, W., Son, S., Nam, J., Xu, Y., Fan, Y., Schwendeman, A., & Moon, J. J.
- Venue
- Science Advances
- Published
- 2018-04-06
- Volume
- 4
- Issue
- 4
- Pages
- eaao1736-eaao1736
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W2802834278
- Cited by
- 352
- References
- 60
- FWCI
- 14.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.